Alkermes Plc Q4 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : When we think about the guidance for 2023 SG&A up around $100 million at the midpoint year-over-year. I imagine much of this is DTC for LYBALVI, but can you quantify that? And how should we think about the annualized DTC cost for LYBALVI as we think ahead to 2024, for example? And then sticking with LYBALVI but on gross to net, I want to make sure I understand what's embedded as it relates to your LYBALVI sales guidance for '23. I think you mentioned high 20s in the first half and that, that may widen depending on if you do additional contracting. So what's baked into the revenue guide in terms of widening in the back half, if anything? Or would that be upside to sales guidance if you opt to not go that route?

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : Just coming back to the Neuroscience SG&A spend. On LYBALVI, just given the breadth of prescribing is driving growth currently, how do you think about your headcount, infrastructure and the commercial operation in 2023 and maybe embedded in those '24 and '25 profitability targets?